6.94

0.57% -0.04

After Hours: 6.94

Fulcrum Therapeutics Inc (FULC)

Overview News Price History Option Chain Financials Discussions Forecast

Fulcrum Therapeutics Inc stock is traded at $6.94, with a volume of 335.34K. It is down -0.57% in the last 24 hours and down -20.50% over the past month. Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Previous Close:

$6.98

Open:

$6.9

24h Volume:

335.34K

Relative Volume:

0.34

Market Cap:

$462.21M

Revenue:

$80.00M

Net Income/Loss:

$-74.88M

P/E Ratio:

-5.8754

EPS:

-1.1812

Net Cash Flow:

$-60.38M

1W Performance:

-1.42%

1M Performance:

-20.50%

6M Performance:

-21.49%

1Y Performance:

+129.80%

1-Day Range:

$6.885

$7.12

1-Week Range:

$6.56

$7.16

52-Week Range:

$2.315

$15.74

Fulcrum Therapeutics Inc Stock (FULC) Company Profile

Name

Fulcrum Therapeutics Inc

Sector

Healthcare (1113)

Industry

Biotechnology (623)

Phone

617-651-8851

Address

26 LANDSDOWNE STREET, CAMBRIDGE, MA

Employee

Twitter

@fulcrumtx

Next Earnings Date

2024-11-05

Latest SEC Filings

FULC's Discussions on Twitter

Compare FULC vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FULC Fulcrum Therapeutics Inc	6.94	464.87M	80.00M	-74.88M	-60.38M	-1.1812
VRTX Vertex Pharmaceuticals Inc	453.74	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	756.73	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.16	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	692.83	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.60	31.97B	606.42M	-1.28B	-997.58M	-6.403

Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-12-26	Initiated	JP Morgan	Overweight
Nov-24-25	Initiated	Truist	Buy
Jul-29-25	Upgrade	H.C. Wainwright	Neutral → Buy
May-23-25	Upgrade	Leerink Partners	Market Perform → Outperform
May-15-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Sep-13-24	Downgrade	H.C. Wainwright	Buy → Neutral
Sep-12-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-12-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Sep-12-24	Downgrade	Leerink Partners	Outperform → Market Perform
Sep-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-12-24	Downgrade	Stifel	Buy → Hold
Sep-09-24	Upgrade	BofA Securities	Underperform → Neutral
May-20-24	Initiated	Cantor Fitzgerald	Overweight
Mar-13-24	Initiated	RBC Capital Mkts	Outperform
Sep-25-23	Initiated	Goldman	Neutral
Aug-23-23	Upgrade	H.C. Wainwright	Neutral → Buy
Aug-22-23	Upgrade	Stifel	Hold → Buy
May-04-23	Downgrade	Goldman	Buy → Neutral
Mar-10-23	Downgrade	Credit Suisse	Outperform → Neutral
Mar-10-23	Downgrade	H.C. Wainwright	Buy → Neutral
Mar-09-23	Downgrade	Stifel	Buy → Hold
Feb-28-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-24-23	Downgrade	BofA Securities	Neutral → Underperform
Nov-15-22	Initiated	Goldman	Buy
Mar-08-22	Initiated	Oppenheimer	Outperform
Mar-03-22	Upgrade	BofA Securities	Underperform → Neutral
Aug-11-21	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Apr-26-21	Resumed	Credit Suisse	Outperform
Mar-22-21	Initiated	Credit Suisse	Outperform
Mar-02-21	Initiated	Stifel	Buy
Oct-16-20	Initiated	Piper Sandler	Overweight
Aug-12-20	Downgrade	BofA Securities	Neutral → Underperform
Aug-12-20	Reiterated	H.C. Wainwright	Buy
Aug-12-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-19-20	Downgrade	BofA/Merrill	Buy → Neutral
Jun-17-20	Initiated	BTIG Research	Buy
Oct-03-19	Initiated	H.C. Wainwright	Buy
Aug-12-19	Initiated	BofA/Merrill	Buy

View All

Fulcrum Therapeutics Inc Stock (FULC) Latest News

Mar 25, 2026

S P Trends: What hedge funds are buying Fulcrum Therapeutics Inc2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn

Mar 25, 2026

Institution Moves: Is Fulcrum Therapeutics Inc forming higher highs and higher lows2026 Earnings Surprises & Weekly Market Pulse Updates - baoquankhu1.vn

Mar 25, 2026

Mar 22, 2026

Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com

Mar 22, 2026

Growth Value: What hedge funds are buying Fulcrum Therapeutics IncMarket Sentiment Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 22, 2026

Mar 21, 2026

Profit Recap: Can Fulcrum Therapeutics Inc deliver alpha2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn

Mar 21, 2026

Mar 20, 2026

Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study - TipRanks

Mar 20, 2026

Mar 19, 2026

Is Fulcrum Therapeutics Inc benefiting from innovation trends2026 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn

Mar 19, 2026

MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times

Mar 19, 2026

MedicAlert Foundation, Sickle Cell Disease Association of - GlobeNewswire

Mar 19, 2026

Mar 16, 2026

Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - MarketBeat

Mar 16, 2026

Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7% - MarketBeat

Mar 16, 2026

Boothbay Fund Management Increases Stake in Fulcrum Therapeutics - National Today

Mar 16, 2026